Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
about
Ultrasensitive detection of DNA and protein markers in cancer cellsA mass spectrometric-derived cell surface protein atlasAcoustophoretic microfluidic chip for sequential elution of surface bound molecules from beads or cellsA Drosophila model of GSS syndrome suggests defects in active zones are responsible for pathogenesis of GSS syndrome.Reproducible ion-current-based approach for 24-plex comparison of the tissue proteomes of hibernating versus normal myocardium in swine modelsLC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions.Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.Quantification of differential ErbB1 and ErbB2 cell surface expression and spatial nanoclustering through plasmon coupling.Phosphoproteomics characterization of novel phosphorylated sites of lens proteins from normal and cataractous human eye lensesAn informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer.Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts.Prioritization of cancer marker candidates based on the immunohistochemistry staining images deposited in the human protein atlas.Improved recovery and identification of membrane proteins from rat hepatic cells using a centrifugal proteomic reactorPlasma membrane proteomic analysis of human Gastric Cancer tissues: revealing flotillin 1 as a marker for Gastric Cancer.An effective plasma membrane proteomics approach for small tissue samples.Oncoproteomics: Trials and tribulations.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarraysAn optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis.Comparative proteomics analysis of degenerative eye lenses of nocturnal rice eel and catfish as compared to diurnal zebrafishGlycoproteomic analysis of the secretome of human endothelial cellsCD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells.Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivoAdvances in the proteomic discovery of novel therapeutic targets in cancer.Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin.Enlightening discriminative network functional modules behind Principal Component Analysis separation in differential-omic science studies.Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.Cell surface markers in colorectal cancer prognosis.Cancer: a proteomic disease.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Mammalian plasma membrane proteins as potential biomarkers and drug targets.Metastasis-associated cell surface oncoproteomics.Application of proteomics in the study of rodent models of cancer.Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery.Mass spectrometry-based membrane proteomics in cancer biomarker discovery.Proteomic approach to understand metastatic spread.Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma.Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy.A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.Crucial considerations for pipelines to validate circulating biomarkers for breast cancer.
P2860
Q26781035-C8D8F63B-8CAB-4ADD-A89E-0DD1D7E742F2Q28546580-E9C19CFB-861B-4716-9726-76252E331C2EQ30449726-BC16B2DD-18DF-4CDF-B8A2-37E569EAC25FQ30509496-2852BEDA-10DD-4CC2-B17F-1B07A1177B77Q33588975-2ABDBDF7-C72D-4B86-A9C8-53D994014B8DQ34118902-EC7C96D4-C889-42A9-B901-A6646D2DD888Q34154644-3253641E-95AC-4274-82B0-3878E8CA3AB0Q34269581-BBB19B09-D3BD-4BA0-A015-D106ED61DEF3Q34511275-BEC4886F-172D-47D9-AB5D-8CBF40DC3F48Q34751614-B828AA94-7068-4992-AA76-734A8090EC96Q34768509-0213CCDE-64A1-4179-B0D4-F34EC26AD55CQ35058538-6422DCEA-E505-4966-A7E3-6AF8582BAA4EQ35497749-4942562A-BC7C-4D1B-8D95-445E27D844EFQ35623711-55D8CA83-DC40-4FF7-9DBE-A8AAB11925C6Q35686877-BF6D3388-FF68-4880-B5B4-15CA31722340Q35827653-F0512C2B-4DDA-4E1A-94D0-2AB8E4E5228DQ35991845-DA733494-08E5-43BF-94EC-0ADB666C4099Q36209001-B9E47F38-C25C-481C-8214-424058145861Q36428301-85471A1F-AEB4-41C9-B87F-9265AD28853AQ36727735-7E4C8CF4-E4F4-4D13-839A-524E90AA0BEDQ36742432-B069C2F4-8A4F-4A87-BC25-4E70C77422CDQ36879247-E573D96B-86EE-4767-A299-B1C7CBF2DD3FQ37086127-5D0F7E64-0264-40B5-A3D9-6920F4B7D61DQ37260569-69E582D8-E993-4AED-B531-7A9DCAC7242DQ37366255-2D0B7C3C-574C-45CC-8F0B-8F4477A10978Q37695361-3815E81E-BE7C-4F8E-BA92-477DAD6D36ACQ37714579-A3958A30-9947-4ADE-A429-1E4183195C6AQ37845669-8DFDBD7D-9678-400E-92FB-3A064E2019CBQ37860196-E4802A9F-3051-49E4-8808-B5728CDF361DQ37863518-8DC5AD6B-C958-4A20-866B-37D7C93EFCFBQ37894617-9E540668-A73E-4037-BCCF-D5192754D346Q38060714-985278F9-FC87-4FB6-9A65-22E52F01E562Q38194543-2CD2373D-4103-465F-A503-20EBE05B009FQ38200653-83774F82-58A4-492A-91D0-563CC8BFBF41Q38211274-BC252243-863C-41C0-863E-38271A85CBD9Q38443346-61DDA44A-C0D8-4676-8BFE-C5095CB35434Q38501662-854C1B6C-E133-46A4-B16C-74B2A4E4C496Q38533591-928A695D-5991-400F-9F83-0D3A34D0E4F5Q38644393-8B618F27-1285-45EB-B753-1C8740BE9749Q38665032-1E74F821-86DC-4BB4-871A-1E855F1B66FA
P2860
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@ast
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@en
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@nl
type
label
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@ast
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@en
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@nl
prefLabel
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@ast
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@en
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@nl
P2093
P2860
P1476
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
@en
P2093
Henrik J Ditzel
Rikke Leth-Larsen
Rikke R Lund
P2860
P304
P356
10.1074/MCP.R900006-MCP200
P577
2010-04-08T00:00:00Z